Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Real-World Safety and Efficacy of Frontline Nivolumab Combined with Doxorubicin, Vinblastine, and Dacarbazine in Adult Classical Hodgkin Lymphoma

HL - 663

Real-World Safety and Efficacy of Frontline Nivolumab Combined with Doxorubicin, Vinblastine, and Dacarbazine in Adult Classical Hodgkin Lymphoma

Ajay Gogia

Poster Presenter: Ajay Gogia

Thumbnail for Real-World Safety Comparison of BTK Inhibitors in Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis of Acalabrutinib, Ibrutinib, and Zanubrutinib

CLL - 1019

Real-World Safety Comparison of BTK Inhibitors in Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis of Acalabrutinib, Ibrutinib, and Zanubrutinib

Vishw Patel

Poster Presenter: Vishw Patel

Previous 1...102 103 104 105 106 107 108...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

$Thumbnail for Real-World Safety Profile of Ciltacabtagene Autoleucel in Triple-Class Refractory Multiple Myeloma: A TriNetX Analysis.$

MM - 881

Real-World Safety Profile of Ciltacabtagene Autoleucel in Triple-Class Refractory Multiple Myeloma: A TriNetX Analysis.

Hira Cheema

Poster Presenter: Hira Cheema

Thumbnail for Real-World Survival and Safety of Isatuximab-Based vs Daratumumab-Based VRd Exposure in Multiple Myeloma

MM - 1202

Real-World Survival and Safety of Isatuximab-Based vs Daratumumab-Based VRd Exposure in Multiple Myeloma

Xiaoyi Zhang

Poster Presenter: Xiaoyi Zhang

Thumbnail for Real-World Survival Outcomes With Pirtobrutinib vs Bendamustine/Rituximab in Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis

CLL - 1140

Real-World Survival Outcomes With Pirtobrutinib vs Bendamustine/Rituximab in Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis

Laraib Jahejo

Poster Presenter: Laraib Jahejo

Thumbnail for Real-World Treatment and Survival Outcomes for Zanubrutinib and Acalabrutinib Monotherapy Among Treatment-Naive Patients With Chronic Lymphocytic Leukemia in the United States

CLL - 160

Real-World Treatment and Survival Outcomes for Zanubrutinib and Acalabrutinib Monotherapy Among Treatment-Naive Patients With Chronic Lymphocytic Leukemia in the United States

Daniel A. Ermann

Poster Presenter: Daniel A. Ermann

Thumbnail for Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With First-Line Pacritinib or Ruxolitinib

MPN - 564

Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With First-Line Pacritinib or Ruxolitinib

Naveen Pemmaraju

Poster Presenter: Naveen Pemmaraju

Thumbnail for Real-World Treatment Patterns and Outcomes With Olutasidenib After Venetoclax in IDH1-Mutated Acute Myeloid Leukemia Using Electronic Health Record Data

AML - 784

Real-World Treatment Patterns and Outcomes With Olutasidenib After Venetoclax in IDH1-Mutated Acute Myeloid Leukemia Using Electronic Health Record Data

Yasmin Abaza

Poster Presenter: Yasmin Abaza

Thumbnail for Real-World Treatment Patterns, Chimeric Antigen Receptor (CAR) T Cell Therapy Referral Barriers, and Time-to-Next Treatment (TTNT) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) Who Experienced Progression =24 Months of First-Line Chemoimmunotherapy (POD24): a United States (US) Claims Analysis

CT - 341

Real-World Treatment Patterns, Chimeric Antigen Receptor (CAR) T Cell Therapy Referral Barriers, and Time-to-Next Treatment (TTNT) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) Who Experienced Progression =24 Months of First-Line Chemoimmunotherapy (POD24): a United States (US) Claims Analysis

Sairah Ahmed

Poster Presenter: Sairah Ahmed

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors